Last 22 quarters of trend data · Healthcare · Medical - Care Facilities
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
biote Corp.'s quarterly P/E stands at 5.6x, up 150.0% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 164.9% YoY to 12.0x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.04 | 5.63 | 10.25 | 3.41 | 10.05 | 2.25 | 15.56 | 4.23 | — | — | 10.29 | 5.33 | — |
| — | +150.0% | -34.1% | -19.4% | — | — | +51.2% | -20.7% | — | — | +142.8% | — | — | |
| P/S Ratio | 0.52 | 0.27 | 0.43 | 0.57 | 0.76 | 0.63 | 1.16 | 0.88 | 1.26 | 1.07 | 0.82 | 0.87 | 0.71 |
| — | -56.9% | -62.7% | -34.5% | -39.5% | -41.5% | +41.8% | +0.4% | +76.8% | +76.7% | +346.8% | +349.8% | +311.6% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 3.29 | 3.43 | 3.09 | 2.06 | 7.04 | 6.36 | 5.10 | 3.31 | 8.70 | 7.95 | 6.26 | — | 5.90 |
| — | -46.0% | -39.5% | -37.9% | -19.1% | -20.0% | -18.5% | — | +47.4% | +268.2% | +342.7% | — | — | |
| EV / EBITDA | 4.72 | 11.98 | 5.33 | 5.11 | 5.07 | 4.52 | 19.33 | 5.08 | 12.78 | 5.28 | 7.78 | 6.74 | 5.77 |
| — | +164.9% | -72.4% | +0.6% | -60.3% | -14.3% | +148.4% | -24.6% | +121.6% | +26.6% | +232.1% | +202.0% | — | |
| EV / EBIT | 5.20 | 11.98 | — | 4.21 | 6.63 | 2.34 | 37.71 | 3.40 | 10.54 | — | 4.56 | 5.07 | — |
| — | +411.5% | — | +23.8% | -37.1% | — | +727.0% | -32.9% | — | — | — | -42.2% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
biote Corp.'s operating margin was 7.0% in Q1 2026, down 7.7 pp QoQ and down 12.7 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 15.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 7.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.5% | 68.9% | 68.0% | 71.8% | 71.6% | 74.3% | 71.3% | 70.5% | 68.9% | 71.3% | 69.4% | 68.9% | 67.9% |
| — | -7.2% | -4.6% | +1.8% | +3.9% | +4.2% | +2.8% | +2.3% | +1.5% | +3.2% | +6.2% | +1.0% | +0.9% | |
| Operating Margin | 18.5% | 7.0% | 14.7% | 17.2% | 22.0% | 19.8% | 5.6% | 23.7% | 12.7% | 22.3% | 12.1% | 16.7% | 15.6% |
| — | -64.4% | +165.0% | -27.3% | +73.8% | -11.2% | -53.9% | +42.2% | -18.6% | +26.8% | -26.6% | -10.4% | +107.5% | |
| Net Margin | 14.1% | 5.1% | 4.2% | 17.1% | 6.5% | 28.0% | 7.4% | 20.8% | -12.9% | -8.9% | 16.9% | 16.5% | -10.4% |
| — | -81.9% | -43.3% | -18.0% | +150.7% | +415.0% | -56.1% | +26.0% | -23.1% | +41.4% | +107.3% | +46198.9% | -65.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 23.5% | 2.3% | 1.8% | 7.6% | 2.8% | 11.2% | 3.3% | 11.0% | -5.0% | -2.6% | 5.1% | 5.2% | -4.0% |
| — | -79.3% | -46.1% | -31.3% | +155.9% | +523.1% | -34.7% | +111.4% | -25.4% | +55.3% | +105.4% | +39108.3% | -64.1% | |
| ROIC | 1129.3% | 5.2% | 21.2% | 55.5% | 85.4% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
biote Corp.'s Debt/EBITDA ratio is 34.2x, up from 14.1x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 9.1% YoY to 1.29x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 2.80 | 34.25 | 14.13 | 11.54 | 9.24 | 10.37 | 28.39 | 9.41 | 18.24 | 10.19 | 20.45 | 14.96 | 14.35 |
| — | +230.2% | -50.2% | +22.6% | -49.3% | +1.8% | +38.8% | -37.1% | +27.1% | -28.0% | +33.4% | +4.8% | — | |
| Current Ratio | 1.22 | 1.29 | 1.22 | 1.01 | 0.98 | 1.42 | 1.32 | 1.50 | 1.34 | 4.75 | 5.51 | 4.69 | 5.16 |
| — | -9.1% | -8.1% | -32.6% | -26.6% | -70.2% | -76.0% | -67.9% | -74.1% | -12.1% | +2.1% | +4.3% | +59.8% | |
| Quick Ratio | 0.79 | 0.58 | 0.79 | 0.72 | 0.74 | 1.14 | 1.03 | 1.16 | 0.92 | 3.97 | 4.73 | 4.25 | 4.82 |
| — | -48.8% | -23.5% | -37.5% | -19.6% | -71.3% | -78.1% | -72.8% | -80.9% | -19.5% | -1.4% | +5.1% | +64.5% | |
| Interest Coverage | 3.24 | 1.61 | -1.99 | 4.09 | 3.13 | 7.01 | 0.62 | 5.48 | 3.16 | -1.00 | 6.22 | 6.76 | -6.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BTMD stock.
biote Corp.'s current P/E is 3.0x. The average P/E over the last 4 quarters is 7.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
biote Corp.'s current operating margin is 18.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking biote Corp.'s business trajectory between earnings reports.